SMAD4 and neoplasm: The key driver of such therapy escape phenomena is likely to be tumor heterogeneity, both on the genetic level, with the four driver genes kras, smad4, tp53 and p16 [4,5] having been shown to lead to distinct survival outcomes [6,7].